FindTrial
Sign In

Artificial Intelligence Based Early Screening of Pancreatic Cancer and High Risk Tracing, ESPRIT-AI

Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037768
Enrollment
Unknown
Registered
2020-08-31
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Case series:No

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Between 18 and 85 years old; 2. Subject is able and willing to provide informed consent and sign an informed consent form; 3. Subject or authorized representative must be willing to complete a detailed questionnaire; 4. Subject must meet one of the following criteria: (1) Familial pancreatic cancer; (2) Hereditary pancreatitis; (3) Chronic pancreatitis; (4) Pancreatic Cystic Neoplasm (including IPMN, MCN); (5) New onset type 2 diabetes (diagnosed within the past 3 years), aged >=50 years old. Must meet one of the following criteria: - Fasting blood glucose (FBG) >=126 mg/dl (7.0 mmol/L); - Hemoglobin A1c (HbA1c) >=6.5%; - Random blood glucose (RBG) >=200 mg/dl (11.1 mmol/L); - 2h Post Glucose (PG) of Oral glucose tolerance test (OGTT) >=200 mg (11.1 mmol/L).

Exclusion criteria

Exclusion criteria: 1. Subject has been diagnosed with pancreatic cancer; 2. Subject has been diagnosed other malignant tumors in the last 5 years; 3. Subject is pregnant or breastfeeding; 4. Subject is suffering from serious primary diseases (such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic disorders), or serious diseases that affect their survival (such as tumor or AIDS), or mentally/legally disabilities; 5. Subject may have potential risks or any other interfering factors (such as frequent job changes may cause loss to follow-up); 6. Subject cannot be followed up or is participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Abdominal Magnetic Resonance Imaging (MRI);Abdominal Computed Tomography (CT);—

Secondary

MeasureTime frame
Blood routine test;Tumor markers (including CA19-9, CEA, CA125, etc.);Liver and kidney function examination;Blood lipid test;Digestive enzymes (including amylase and lipase);Four coagulation tests;—

Countries

China

Contacts

Public ContactJin Gang

Shanghai Changhai Hospital

jingang@smmu.edu.cn+86 13601635681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026